Drug information of Diclofenac
Mechanism of effect
The mechanism of action of Diclofenac Sodium Extended-release Tablets, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.
Diclofenac Sodium Extended-release Tablets are a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models
Completely absorbed from the gastrointestinal tract. Diclofenac is more than 99% bound to human serum proteins, primarily to albumin.
Metabolism:Hepatic Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged Diclofenac plus metabolites.
Usual Adult Dose for Osteoarthritis Diclofenac free acid capsules:
35 mg orally 3 times a day
Diclofenac potassium immediate-release tablets: 50 mg orally 2 or 3 times a day
Diclofenac sodium enteric-coated tablets: 50 mg orally 2 or 3 times a day or 75 mg orally 2 times a day
Maximum dose: 150 mg daily
Diclofenac sodium extended-release tablets: 100 mg orally once a day
Usual Adult Dose for Pain
Diclofenac potassium liquid-filled capsules: 25 mg orally 4 times a day Diclofenac free acid capsules: 18 mg or 35 mg orally 3 times a day
potassium immediate-release tablets: 50 mg orally 3 times a day; an initial dose of 100 mg orally followed by 50 mg oral doses may provide better relief in some patients.
Parenteral: 37.5 mg IV bolus over 15 seconds every 6 hours as needed for pain Maximum Dose: 150 mg per day
Drug contraindicationshypersensitivity to drug or its components. , In the setting of coronary artery bypass graft (CA
Side effectsnausea , Hematuria , dizziness , Angioedema , allergic reaction , rash , vertigo , Diarrhea , bronchospasm , GI bleeding , Tinnitus
InteractionsAmitriptyline , Amikacin , Acetylcholine , Tanacetum parthenium , Feverfew , Tenofovir , Gentamicin , Dactinomycin , Drospirenone , Deferiprone , Furosemide , Sawpalmatto , Sawpalmatto complex , Cyclosporine , cefepime , Donepzil , Doxazosin , teriflunomide , Meglumine Compound , Apixaban , Desirudin , Loteprednol , Travoprost , Carbocisteine , Ginkgo biloba , Eprosartan , Peginterferon alfa-2b , fenoprofen , Trandolapril , Pirfenidone , Pemetrexed , Tositumomab , Ibritumomab tiuxetan , Benazepril , aminolevulinic acid oral , Aminolevulinic acid topical , Diatrizoate (Amidotrizoic acid) , Betrixaban , Ramucirumab , Bromfenac , Moexipril , Ioxaglate , Cordyceps , Netonal , Iothalamate Meglumine , Urokinase , Dasatinib , Remdesivir , Cannabidiol , vortioxetine , Artesunate , Aminohippurate Sodium
1-To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible.
2-Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected.
3-If Diclofenac Sodium Extended-release Tablets therapy must be initiated, close monitoring of the patient's renal function is advisable.
4-Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of liver injury.
5-NSAIDs, including Diclofenac Sodium Extended-release Tablets, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
Points of recommendation
1-In late pregnancy, as with other NSAIDs, Diclofenac Sodium Extended-release Tablets should be avoided because it will cause premature closure of the ductus arteriosus.
2-Take with food to reduce irritation.